Showing 4261-4270 of 5000 results for "".
- Industry Responds to COVID-19: Dial Donates Products to FEMA, Encourages Americans to Participate in #IWashMyHandsFor Social Campaignhttps://practicaldermatology.com/news/industry-responds-dial-donates-products-to-fema-encourages-americans-to-participate-in-iwashmyhandsfor-social-campaign/2460398/Dial will donate more than 600,000 units of liquid hand soap, bar soap and body wash products to FEMA, supporting their mission to help people during disasters. In March 2020 Henkel announced a comprehensive
- AAD: Sixty Percent of Americans Have Gotten Sunburned So Badly Their Clothes Were Uncomfortablehttps://practicaldermatology.com/news/aad-sixty-percent-of-americans-have-gotten-sunburned-so-badly-their-clothes-were-uncomfortable/2460396/Most Americans say they have gotten a sunburn and admit it has impacted their day-to-day life, according to a recent AAD survey. Of those who have been sunburned, 60 percent said their sunburns made their clothes uncomfortable; 43 percent said they couldn’t sleep; and 21 percent said they w
- To Test or Not to Test? Practices Weigh COVID-19 Testing of Patients and Staff as Part of Reopening Planshttps://practicaldermatology.com/news/to-test-or-not-to-test-practices-weigh-covid-19-testing-of-patients-and-staff-as-part-of-reopening-plans/2460395/COVID-19 antibody testing can play an important role in identifying people who have recovered from the SARS-CoV-2 virus and who have high levels of antibodies in their blood that could potentially help other critically ill COVID-19 patients. The presence of antibodies may also suggest immuni
- COVID-19 By the Numbers: April 28 Editionhttps://practicaldermatology.com/news/covid-19-by-the-numbers-april-28-edition/2460365/The CDC now lists nine potential symptoms of COVID-19, though cough and shortness of breath or difficulty breathing remain hallmarks of the disease. CDC says individuals may have COVID-19 if they experience these two symptoms plus at least two of the following: Fever
- MD Survey: Telehealth Booming, Prescribing Habits Changing During Pandemichttps://practicaldermatology.com/news/md-survey-telehealth-booming-prescribing-habits-changing-during-pandemic/2460360/More than four-fifths of physicians saw fewer patients in late March, averaging 40 patients per week vs. 103 per week prior to March 2020, according to a new survey of 500 U.S physicians by AbelsonTaylor, a health and wellness marketing agency. What’s more, three-quarters of physi
- Label Expansion: Amgen's Otezla Adds Scalp Datahttps://practicaldermatology.com/news/label-expansion-amgens-otezla-adds-scalp-data/2460359/With FDA approval of a supplemental New Drug Application (sNDA), the label for Amgen's Otezla will now be updated to include scalp psoriasis data from the Phase 3 STYLE trial. The label expansion makes Otezla the only oral treatment option to have data specific to moderate
- AAD Elects New Officers, Board Membershttps://practicaldermatology.com/news/aad-elects-new-officers-board-members/2460358/Mark D. Kaufmann, MD, FAAD, has been elected to lead the American Academy of Dermatology. He will be installed as president-elect in March 2021 and hold the office of president for one year beginning in March 2022. Dr. Kaufmann, who is a member of the Practical Dermatology®
- Coping with COVID-19: Tips and Tools for Enhancing Virtual Skin Cancer Examshttps://practicaldermatology.com/news/coping-with-covid-19-tips-and-tools-for-enhancing-virtual-skin-cancer-exams-1/2460356/Dermatologists across the country have shut their doors due to the coronavirus pandemic, and little certainty remains about when they will reopen for business as usual. Many are still seeing patients with aggressive squamous cell carcinoma or melanoma, but these patients need to be effectively tr
- Can JAK Inhibition Put the Brakes on COVID-19-Associated Cytokine Storm? Incyte Hopes Sohttps://practicaldermatology.com/news/can-jak-inhibition-put-the-brakes-on-covid-19-associated-cytokine-storm-incyte-hopes-so/2460355/Incyte’s JAK inhibitor may play a role in stopping COVID-19-associated cytokine storms. Incyte is starting RUXCOVID, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of ruxolit
- DermWire Exclusive: Inside the COVID-19 Outbreak in Italy with Dr. Sebastiano Recalcatihttps://practicaldermatology.com/news/dermwire-covid-19-exclusive-inside-the-outbreak-in-italy-with-sebastiano-recalcati/2460352/Dr. Sebastiano Recalcati, a dermatologist in Lombardy, Italy, was one of many doctors called to the frontlines in that country when COVID-19 ravaged the region. He published his observations in the Journal